Cargando…
Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
Autores principales: | Million, Matthieu, Giraud-Gatineau, Audrey, Lagier, Jean-Christophe, Parola, Philippe, Gautret, Philippe, Raoult, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733546/ https://www.ncbi.nlm.nih.gov/pubmed/33316396 http://dx.doi.org/10.1016/j.tmaid.2020.101954 |
Ejemplares similares
-
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
por: Gautret, Philippe, et al.
Publicado: (2021) -
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
por: Gautret, Philippe, et al.
Publicado: (2021) -
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
por: Million, Matthieu, et al.
Publicado: (2021) -
Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
por: Million, Matthieu, et al.
Publicado: (2023) -
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
por: Gautret, Philippe, et al.
Publicado: (2021)